Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients

Clinical Epigenetics

Table 1 Patient characteristics

ALK-positive NSCLC patients (n = 21; n = 66 plasma specimens)
Age, median (range)	56 (42–80)
Sex, male	11/21
Stage IV	21/21
ALK fusion variant, patient number¹
EML4-ALK V1/V2	11
EML4-ALK V3	7
Other²	2
No data	1
TP53 status, patient number¹
Positive	6
Negative	14
No data	1
Treatment, sample number
Crizotinib	19
Ceritinib, Alectinib, Brigatinib	27
Lorlatinib	5
Chemotherapy	10
Naïve	4
No data	1
Number of samples per patient, mean (range)	3.1 (1–14)
Radiological evaluation at sampling, number of samples
Extracranial PD	27
Intracranial PD	4
SD	30
PR	2
No data	3

ALK anaplastic lymphoma kinase, EML4 echinoderm microtubule-associated protein-like 4, KCL1 kinesin light chain 1, NGS next-generation sequencing, PD progressive disease, PR partial response, SD stable disease, TP53 tumor protein 53
¹Data available for 20/21 patients from NGS of tissue biopsies at diagnosis of stage IV disease
²One patient with a K9A20 (KCL1) and one with an E9A10 fusion

ISSN: 1868-7083